Immunohistochemical investigation of the expression of biglycan and integrin beta 1 in melanoma as a prognostic marker for progression-free and overall survival
Recruiting
- Conditions
- C43Malignant melanoma of skin
- Registration Number
- DRKS00010086
- Lead Sponsor
- niversitätsklinikum Freiburg
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 150
Inclusion Criteria
Availability of archival tumor material of
1.Primary melanoma with good prognosis
2.Primary melanoma with intermediate prognosis
3.Primary melanoma with poor prognosis
4.Primary melanoma with and without sentinel node involvement
5.Melanoma metastases
Exclusion Criteria
No archival tumor material available. Follow-up information of outcome parameters not available.
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method overall survival
- Secondary Outcome Measures
Name Time Method survival without progression